Lucida Medical launches next generation software to support advanced clinical decisions in the prostate cancer pathway
8 April 2026 – Cambridge, UK
Lucida Medical has released a major update to its AI solution, Prostate Intelligence™ (Pi™), furthering its mission to improve the prostate cancer pathway. The enhanced version provides clearer, more consistent assessment of the risk of clinically significant prostate cancer and supports reductions in unnecessary biopsies.
The new version enables clinicians to bring together AI risk score generated by Pi™, PSA density and PIRADS® assessments in a single integrated risk score within the user interface. This supports more consistent, evidence based decisions, particularly for challenging PIRADS® 3 cases.
The design of this feature is informed by findings from a study published in European Radiology, AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study, which showed that combining PI-RADS®, PSA density and AI risk scores given by Pi™ could reduce unnecessary biopsies by around 20% in the validation cohort while maintaining detection of clinically significant cancers. These results support the value of presenting key clinical and imaging information together, as implemented in the updated Pi™ user interface.
The release also adds the option to review and update Pi™ generated lesion segmentations before sending results to PACS. Radiologists can adjust or remove existing segmentations or draw additional ones as needed. This provides a clear accept-or-revise workflow and ensures that final PI-RADS® scoring accurately reflects the clinician’s interpretation.
Other updates include general performance and workflow improvements designed to support smoother case review and more consistent integration with clinical systems.
If you are interested in learning more about this software release or discussing how Pi™ can support your clinical workflow, do not hesitate to reach out to us.
Lucida Medical
Lucida Medical is a UK medical technology company developing artificial intelligence to help clinicians detect prostate cancer earlier and more accurately from MRI. Its flagship solution, Pi™ (Prostate Intelligence), analyses prostate MRI scans to highlight suspicious lesions and generate risk scores that support radiologists’ decisions. CE‑certified and deployed across NHS hospitals and Europe, Pi™ has been trained and validated on thousands of patient scans. Clinical research across multiple NHS Trusts has shown the system can detect clinically significant prostate cancer with performance comparable to expert radiologists.
For media inquiries, please contact:
Roberta Belanova